Finding new therapies for Parkinson's disease (PD) is a slow process. We assembled an international committee of experts to examine drugs potentially suitable for repurposing to modify PD progression. This committee evaluated multiple drugs currently used
One of the most common neurodegenerative disorders is Parkinson's disease. The occurrence of Parkins...
After many years of preclinical development, cell and gene therapies have advanced from research too...
Objective: A 'case scenario' study on clinical decisions in progressing Parkinson's disease (PD) was...
The development of an intervention to slow or halt disease progression remains the greatest unmet th...
© 2013 – IOS Press and the authors. All rights reserved This article is published online with Open A...
Translating new findings in the laboratory into therapies for patients is a slow and expensive proce...
An increase in the efficiency of clinical trial conduct has been successfully demonstrated in the on...
An increase in the efficiency of clinical trial conduct has been successfully demonstrated in the on...
Parkinson's disease (PD) is a common neurodegenerative disease typified by a movement disorder consi...
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that currently has no cure, but...
Abstract Parkinson's disease is a highly disabling, progressive neurodegenerative disease that manif...
In 2018, developments in Parkinson disease (PD) research yielded improved diagnostic criteria and pr...
Since half of the world's older population lives in Asia, neurodegenerative diseases including Park...
New treatment options that are being researched for slowing or stopping the progression of Parkinson...
Stages in a-syn aggregation Further studies in progress • We are currently carrying out an extensive...
One of the most common neurodegenerative disorders is Parkinson's disease. The occurrence of Parkins...
After many years of preclinical development, cell and gene therapies have advanced from research too...
Objective: A 'case scenario' study on clinical decisions in progressing Parkinson's disease (PD) was...
The development of an intervention to slow or halt disease progression remains the greatest unmet th...
© 2013 – IOS Press and the authors. All rights reserved This article is published online with Open A...
Translating new findings in the laboratory into therapies for patients is a slow and expensive proce...
An increase in the efficiency of clinical trial conduct has been successfully demonstrated in the on...
An increase in the efficiency of clinical trial conduct has been successfully demonstrated in the on...
Parkinson's disease (PD) is a common neurodegenerative disease typified by a movement disorder consi...
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that currently has no cure, but...
Abstract Parkinson's disease is a highly disabling, progressive neurodegenerative disease that manif...
In 2018, developments in Parkinson disease (PD) research yielded improved diagnostic criteria and pr...
Since half of the world's older population lives in Asia, neurodegenerative diseases including Park...
New treatment options that are being researched for slowing or stopping the progression of Parkinson...
Stages in a-syn aggregation Further studies in progress • We are currently carrying out an extensive...
One of the most common neurodegenerative disorders is Parkinson's disease. The occurrence of Parkins...
After many years of preclinical development, cell and gene therapies have advanced from research too...
Objective: A 'case scenario' study on clinical decisions in progressing Parkinson's disease (PD) was...